TEJNAKSH HEALTHCARE LIMITED
Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

12TH Feb 2025,

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Sub: Integrated Filing (Financials) for the quarter and nine months ended 31st December 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated Filing (Financials) of the Company, in the specified format for the quarter and nine months ended 31st December 2024.

Request you to kindly take the same on record as required under the provisions of the above captioned Regulation.

Thanking you.

For Tejnaksh Healthcare Limited

ASHISH VISHWAS RAWANDALE
Digitally signed by ASHISH VISHWAS RAWANDALE
Date: 2025.02.12 14:40:26 +05'30'

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

TEJNAKSH HEALTHCARE LIMITED
Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

QUARTERLY INTEGRATED FILING-(FINANCIAL)

A. Financial Results for quarter ended 31st December, 2024 – Attached
B. Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. – Not Applicable
C. Format for disclosing outstanding default on loans and debt securities- Not Applicable
D. Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e.,2nd and 4th quarter) - Not Applicable
E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along with annual audited financial results (standalone and consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable for Quarter ended 31st December, 2024.

For Tejnaksh Healthcare Limited

ASHISH VISHWAS RAWANDALE

Digitally signed by ASHISH VISHWAS RAWANDALE
Date: 2025.02.12 14:40:55 +05'30'

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER & NINE MONTH ENDED DECEMBER 31, 2024
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec-24	Sep-24	Dec-23	Dec-24	Dec-23	Mar-24
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
REVENUE						
Revenue from operations (net)	223.82	197.98	210.11	639.35	607.90	822.15
Other income	13.92	8.21	6.57	29.03	21.38	27.84
Total Revenue (I)	**237.74**	**206.19**	**216.68**	**668.38**	**629.29**	**849.99**
EXPENSES						
Cost of Materials Consumed	0.05	(1.01)	2.87	0.14	9.80	15.78
Purchases of stock-in-trade	7.38	19.96	13.06	43.30	45.85	62.17
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(0.48)	(3.31)	2.83	0.69	(2.21)	(9.86)
Employee benefits expense	16.93	18.43	18.62	55.24	59.02	79.33
Finance costs	11.25	10.57	19.57	33.58	53.62	68.59
Depreciation and amortization expense	17.15	26.68	20.09	63.83	60.33	80.02
Other expenses	64.12	71.65	66.43	208.97	240.64	310.80
Total Expenses (II)	**116.40**	**142.97**	**143.48**	**405.75**	**467.05**	**606.83**
Profit before tax (I) - (II)	**121.34**	**63.22**	**73.20**	**262.63**	**162.24**	**243.16**
Tax expense:						
Current tax	33.78	12.61	13.32	62.21	26.01	41.31
Deferred tax	15.62	(5.69)	5.10	13.81	15.52	20.60
Profit for the period/year	**71.94**	**56.30**	**54.78**	**186.61**	**120.69**	**181.26**
OTHER COMPREHENSIVE INCOME						
Other Comprehensive income/loss						
Items not be reclassified to profit or loss :						
Remeasurement of defined employee benefit plans	0.62	0.62	0.42	1.86	1.27	2.48
Income tax credit(expense) relating to above items	(0.16)	(0.15)	(0.11)	(0.47)	(0.32)	(0.62)
Total Other Comprehensive income for the year, net of tax	**0.46**	**0.47**	**0.32**	**1.39**	**0.95**	**1.86**
TOTAL COMPREHENSIVE INCOME (NET OF TAX) FOR THE PERIOD/YEAR	**72.40**	**56.77**	**55.10**	**188.00**	**121.64**	**183.11**
Paid Up Equity Share Capital (face value 5/- each	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous period						1,261.98
Earnings per share (EPS)						
Equity shares (fair value of 5/-)						
Basic and Diluted Earing Per Share	0.36	0.31	0.27	0.92	0.59	0.89
	Not Annualized					

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Notes to the Unaudited Standalone Financial Results for the quarter and nine month ended December 31, 2024

1. The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 11, 2025. The Statutory Auditors of the Company have carried out a limited review of the standalone unaudited financial results for the quarter and nine month ended on December 31, 2024. Their limited review report does not have any modification.

2. The above unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. Figures for the quarter ended December 31, 2024 are derived from figures between the figures in respect of the period ended December 31, 2024, and figures for the quarter ended September 30, 2024.

4. As the Company operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

5. Figures for the previous year/periods have been regrouped and reclassified to confirm the classification of the current year/period, where necessary.

Tejnaksh Healthcare Limited MUMBAI

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: February 11, 2025
Place: Mumbai

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the quarterly and year-to-date ended December 31, 2024 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Company') for the quarter and December 31, 2024 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations)

2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

Vikas Asawa
Partner
Membership No.: 172133
UDIN: 25172133BMHZSO9776

Place: Mumbai
Date: February 11, 2025.

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

TEJNAKSH HEALTHCARE LIMITED
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER & NINE MONTH ENDED DECEMBER 31, 2024
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec-24	Sep-24	Dec-23	Dec-24	Dec-23	Mar-24
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
REVENUE						
Revenue from operations (net)	318.98	336.86	313.59	968.22	925.30	1,217.51
Other income	17.42	8.58	7.34	33.22	23.61	30.66
Total Revenue (I)	**336.40**	**345.44**	**320.92**	**1,001.44**	**948.91**	1,248.17
EXPENSES						
Cost of Materials Consumed	0.05	(1.01)	2.85	0.14	9.78	15.78
Purchases of stock-in-trade	60.08	4.07	30.45	95.32	95.74	124.33
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(3.20)	(5.18)	2.48	(5.48)	(3.70)	(13.33)
Employee benefits expense	44.21	34.51	32.27	113.57	101.75	136.88
Finance costs	14.27	10.58	18.52	36.62	50.59	64.44
Depreciation and amortization expense	20.12	30.62	22.70	73.54	68.02	90.59
Other expenses	104.27	188.80	139.68	428.09	450.69	591.98
Total Expenses (II)	**239.81**	**262.39**	**248.94**	**741.79**	**772.86**	1,010.66
Profit before tax (I) - (II)	**96.60**	**83.05**	**71.98**	**259.65**	**176.05**	**237.50**
Tax expense:						
Current tax	30.03	18.15	12.82	63.99	29.21	41.93
Deferred tax	11.03	(0.41)	5.29	14.94	16.12	19.18
Profit for the period/year	**55.54**	**65.31**	**53.87**	**180.72**	**130.72**	**176.39**
OTHER COMPREHENSIVE INCOME						
Other Comprehensive income/loss						
Items not be reclassified to profit or loss :						
Remeasurement of defined employee benefit plans	(1.56)	0.78	0.81	-	2.44	3.12
Income tax credit(expense) relating to above items	2.75	(0.21)	(0.20)	2.34	(0.61)	(0.78)
Other Comprehensive income for the year, net of tax	**1.19**	**0.57**	**0.61**	**2.34**	**1.83**	**2.33**
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	**56.73**	**65.88**	**54.48**	**183.06**	**132.55**	**178.72**
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous period						1,340.96
Earnings per share (EPS)						
Equity shares (fair value of 5/-)						
Basic and Diluted Earing Per Share	0.38	0.31	0.27	0.98	0.63	0.87
	Not Annualized					

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Corp. Off. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
Head Off. : Institute of Urology, Sakri Road, Dhule - 424001
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 – 2754 2311, 02562 - 245322/ 245995

Notes to the Unaudited Consolidated Financial Results for the quarter and nine month ended December 31, 2024

1. The above unaudited Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 11, 2025. The Statutory Auditors of the Company have carried out a limited review of the Consolidated unaudited financial results for the quarter and nine month ended on December 31, 2024. Their limited review report does not have any modification.

2. The above unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. Figures for the quarter ended December 31, 2024 are derived from figures between the figures in respect of the period ended December 31, 2024, and figures for the quarter ended September 30, 2024.

4. As the Group operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

5. Figures for the previous year/periods have been regrouped and reclassified to confirm the classification of the current year/period, where necessary.

Tejnaksh Healthcare Limited MUMBAI

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: February 11, 2025
Place: Mumbai

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited for the quarterly and year-to-date ended December 31, 2024 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Parent') and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2024 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations).

2. This Statement which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
   a. Holding Company: Tejnaksh Healthcare Limited
   b. Subsidiary: Tej Vedaant Healthcare Private Limited

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

MAHESHWARI & CO. FRN : 105834W MUMBAI Chartered Accountants

Vikas Asawa
(Partner)
Membership No.: 172133

Place: Mumbai
Date: February 11, 2025

UDIN: 25172133BMHZSN6877